Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients

Basit Öğe Kaydı
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorTekgunduz, Emre
dc.contributor.authorEdis, Mustafa
dc.contributor.authorDuran, Enver
dc.contributor.authorKurum, Turan
dc.contributor.authorYigitbasi, Omer
dc.contributor.authorYuksel, Mahmut
dc.date.accessioned2024-06-12T11:03:07Z
dc.date.available2024-06-12T11:03:07Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: Heparin-induced thrombocytopenia (HIT) is a life threatening complication of heparin therapy, causing thrombosis. The aim of our study was to find out the frequencies of HIT antibody seroconversion and clinical HIT in Turkish medical patients on different forms of heparins. Materials and Methods: Our study included 61 patients who were an unfractionated heparin (UFH) (n: 37) and low molecular weight heparin (LMWH) (n: 24) therapies. The frequency of HIT antibody formation was determined by means of antigenic (ELISA), and functional assays (serotonin release assay-SRA). Results: The seroconversion rates in UFH and LMWH groups were found to be 18.9% and 4.1% (ELISA), and 8.1% and 4.1% (SRA), respectively. One patient (2.1%) on UFH therapy developed deep vein thrombosis. No thromboembolic event was observed in patients taking LMWH. Conclusion: Seroconversion rates by means of antigenic and functional assays and clinical HIT were more common in patients on UFH than patients on LMWH therapy. (Turk J Hematol 2009; 26: 171-5)en_US
dc.identifier.endpage175en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4en_US
dc.identifier.pmid27265628en_US
dc.identifier.scopus2-s2.0-73649123833en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage171en_US
dc.identifier.trdizinid99306en_US
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/99306
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21542
dc.identifier.volume26en_US
dc.identifier.wosWOS:000272964200003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHeparin-Induced Thrombocytopeniaen_US
dc.subjectMedical Patientsen_US
dc.subjectTurkish Cohorten_US
dc.subjectUnfractionated Heparinen_US
dc.subjectLow Molecular Weight Heparinen_US
dc.subjectMolecular-Weight Heparinen_US
dc.subjectProspective Cohorten_US
dc.titleIncidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu